Abstract 3438
Background
To compare the effects of high biologically effective dose (BED) and low BED radiotherapy for small cell lung cancer (SCLC) with brain metastases (BMs), and identify the prognostic factors of survival.
Methods
A total of 250 consecutive SCLC (stage II-IV) with BMs patients in our institution were retrospectively analyzed, from January 1998 to June 2018. Preliminary screening of the prognostic factors was accomplished by Kaplan-Meier univariate analysis. Baseline covariates were balanced by a propensity score model. And survival curves between the two groups were compared by the log-rank test. The Cox regression model was used to analyze factors associated with prognosis.
Results
The Cutoff Finder program exported an optimal BED cutoff value of 47 for all patients. The high-BED (>47 Gy) group had a significantly better OS than low-BED (≤47 Gy) group (median OS: 17.5 vs. 9.5, P < 0.001). Multivariate analysis found that BED (P < 0.001), smoking (P = 0.017), ECOG score (P = 0.047) and age (P = 0.004) were independently prognostic factors affecting OS. And after 1:2 propensity score matching, 163 patients were divided into the high-BED group (n = 57) and the low-BED group (n = 106). In the matched cohort, OS was significantly higher in the high-BED group than low-BED group (P < 0.001).
Conclusions
BED, smoking, ECOG score, age were observed to affect the OS of SCLC patients with BMs. High BED radiotherapy (>47 Gy) might improve long-term survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Qingyang, Zhuang.
Funding
The Fujian Province Natural Science Foundation (2017J01260), Joint Funds for the Innovation of Science and Technology, Fujian province (2017Y9074), and the Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education/Beijing (2017 Open Project-9).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5037 - CXCR4, CCR2 and CCR5 expression in subsets of tumor cells with stem and/or EMT features
Presenter: Olga Savelieva
Session: Poster Display session 1
Resources:
Abstract
5729 - Expression of mutant p53 affects cancer cell sensitivity to topotecan
Presenter: Rimma Mingaleeva
Session: Poster Display session 1
Resources:
Abstract
5725 - Breast cancer organoids a new tool for the prediction of drugs penetration and patient’outcome
Presenter: Giuseppina Roscigno
Session: Poster Display session 1
Resources:
Abstract
5680 - Aptamer-mediated exosomes detection for early breast cancer identification.
Presenter: Cristina Quintavalle
Session: Poster Display session 1
Resources:
Abstract
2460 - MicroRNA-181c promotes tamoxifen resistance in breast cancer cells via upregulation Akt/mTOR axis
Presenter: Alexander Scherbakov
Session: Poster Display session 1
Resources:
Abstract
3751 - Spatio-temporal separation of tumor infiltrating CD8+ T-cells and HER2/neu+ tumor cells in tumor-immune milieu of infiltrating ductal carcinoma of the breast
Presenter: Sandhya Sreedharan
Session: Poster Display session 1
Resources:
Abstract
4664 - Large genomic rearrangements in BRCA1 and BRCA2 genes in the Portuguese population.
Presenter: Joao Pinto
Session: Poster Display session 1
Resources:
Abstract
4611 - Non-BRCA1/2 hereditary breast and ovarian cancer: findings from a multidisciplinary program
Presenter: Ana Monteiro
Session: Poster Display session 1
Resources:
Abstract
5340 - Quantitative imaging and characterization of collagen patterns in high grade serous ovarian carcinoma (HGSOC)
Presenter: Ruby Huang
Session: Poster Display session 1
Resources:
Abstract
4209 - Semiquantitative assessment of vimentin expression in prostate cancer (PC)
Presenter: Marina Puchinskaya
Session: Poster Display session 1
Resources:
Abstract